Lyell Immunopharma announced positive updated data for ronde-cel, a dual-targeting CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (LBCL). In trials, ronde-cel achieved over 90% overall response rates and around 75% complete response rates in both third-line and second-line patient groups, with durable remissions and no severe cytokine release syndrome observed. These promising results support ongoing regulatory submissions and presentations at ASH 2026, highlighting ronde-cel's potential to improve outcomes for lymphoma patients.
Lyell Immunopharma's updated ronde-cel data for relapsed/refractory large B-cell lymphoma provides context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 04, 2026 19:41 WIB: out of 150 priced US health-sector stocks, 121 rose and 23 fell. Notable movers include HRTX at USD 0.30 (+5.37%, 34% Sell / 66% Buy, typical hold time 38 days), THC at USD 281.00 (+5.37%, 100% Sell / 0% Buy, typical hold time 17 days), and TLRY at USD 2.77 (+4.53%, 96% Sell / 4% Buy, typical hold time 32 days).
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
